Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
VIS-954 by Visterra for Transplant Rejection: Likelihood of Approval
VIS-954 is under clinical development by Visterra and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I...
Data Insights
VIS-954 by Visterra for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
VIS-954 is under clinical development by Visterra and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According...